Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Nadofaragene firadenovec is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium. 55 (53%) of 103 patients with carcinoma in situ had a complete response within 3 months of the first dose.

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Stereotactic ablative body radiotherapy(SABR) is increasingly being used to treat oligometastatic cancers, but high-level evidence to provide a basis for policymaking is scarce. SABR was commissioned by NHS England in March 2020 as a treatment option. Between June 15, 2015, and Jan 30, 2019, 1422 patients were recruited from 17 hospitals in England. The median age of the patients was 69 years and the most common tumor was prostate cancer.

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

A fixed-dose subcutaneous formulation of pertuzumab and trastuzumAB with hyaluronidase was approved by the FDA. The Federica study was designed to assess the pharmacokinetics, efficacy, and safety of the formulation. Safety was similar between treatment groups, and in line with other pertuzumab, trastuzumab, and chemotherapy trials.

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We did a multicentre, open-label, randomized, controlled, phase 3 trial in 139 sites. Eligible patients were women aged 20–75 years with stage I to IIIB invasive breast cancer. As the primary endpoint was met, the trial was terminated early.

The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis

Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimize risk to patients and staff. We aimed to assess the national impact of the pandemic on the prescribing of anticancer treatment in England. After the onset of the COVID-19 pandemic, there was a reduction in anticancer treatment initiation in England.

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

CASPIAN is an ongoing, open-label, sponsor-blind, randomized, controlled phase 3 trial at 209 cancer treatment centers in 23 countries. Eligible patients were aged 18 years or older with extensive-stage small-stage lung cancer (ES-SCLC).

Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study

Watch and wait is a novel management strategy in patients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy. Surveillance of these patients is intensive because local regrowth occurs in 25% of patients. It is unclear how long these patients should be followed up.

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

RAPIDO trial aimed to reduce distant metastases without compromising locoregional control. Participants were recruited from 54 centers in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA. Median follow-up was 4.6 years. The experimental treatment can be considered as a new standard of treatment in high-risk locally advanced rectal cancer.

Departments

Recent Posts